This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kohno, H. Articles by Tanaka, T. Search for Related Content PubMed PubMed Citation Articles by Kohno, H. Articles by Tanaka, T. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Dietary Supplementation with Silymarin Inhibits 3,2'-Dimethyl-4-Aminobiphenyl–Induced Prostate Carcinogenesis in Male F344 Rats

Authors' Affiliations: ¹ Department of Oncologic Pathology, Kanazawa Medical University, Ishikawa, Japan and ² Department of Molecular Toxicology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Requests for reprints: Hiroyuki Kohno, Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, 920-0293 Ishikawa, Japan. Phone: 81-76-286-2211; Fax: 81-76-286-6926; E-mail: h-kohno{at}kanazawa-med.ac.jp.

Purpose: Silymarin has been shown to be a potent anticarcinogenic agent. Here, we investigated the modifying effects of dietary feeding with a naturally occurring polyphenolic antioxidant flavonoid silymarin on 3,2'-dimethyl-4-aminobiphenyl (DMAB)–induced prostatic carcinogenesis in male F344 rats.

Experimental Design: Male F344 rats were given s.c. injections of DMAB (25 mg/kg body weight) every other week for 20 weeks. They also received the experimental diet containing 100 or 500 ppm silymarin for 40 weeks, starting 1 week after the last dosing of DMAB. All of the rats were sacrificed 60 weeks after the start of the experiment. Histopathology and immunohistochemistry for proliferative cell nuclear antigen, cyclin D1, and apoptotic indices were done in the prostatic lesions, including invasive adenocarcinomas, intraepithelial neoplasms, and nonlesional glands.

Results: Dietary feeding with 500 ppm silymarin significantly inhibited the incidence of prostatic adenocarcinoma when compared with the DMAB-alone group (17.6% versus 50.0%, P < 0.05). The proliferative cell nuclear antigen– and cyclin D1–positive indices in adenocarcinomas, prostatic intraepithelial neoplasm, and nonlesional glands in rats treated with DMAB and silymarin were slightly lower than that of the DMAB-alone group. Also, dietary administration of silymarin increased apoptotic index in prostatic adenocarcinoma by measuring immunohistochemically positive nuclei for ssDNA.

Conclusions: Our results indicate that silymarin exerts chemopreventive ability against chemically induced prostatic carcinogenesis through apoptosis induction and modification of cell proliferation.

This article has been cited by other articles:

				G. Deep, N. H. Oberlies, D. J. Kroll, and R. Agarwal Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells Carcinogenesis, July 1, 2007; 28(7): 1533 - 1542. [Abstract] [Full Text] [PDF]

				G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]